manilatimes.net · Jun 1, 2026 03:09 UTC

ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential

Summary

CHICAGO, June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead ass...

Original reporting

Open original source

Related coverage

Read full article on manilatimes.net